| |||
 | |||
 |
Passionflower | ||
| |||
| |||
| |||
|
Dehydroepiandrosterone (DHEA) | ||
|
| |||
| U.S. Brand Names |
| Mebaral® |
 |
| Generic Available |
|
No |
|
| Synonyms |
| Methylphenobarbital |
|
| Pharmacological Index |
|
Barbiturate |
|
| Use |
|
Sedative; treatment of grand mal and petit mal epilepsy |
|
| Restrictions |
|
C-IV |
|
| Pregnancy Risk Factor |
|
D |
|
| Contraindications |
|
Hypersensitivity to mephobarbital, other barbiturates, or any component; pre-existing CNS depression; respiratory depression; severe uncontrolled pain; history of porphyria |
|
| Adverse Reactions |
|
>10%: Central nervous system: Dizziness, lightheadedness, drowsiness, "hangover" effect 1% to 10%: Central nervous system: Confusion, mental depression, unusual excitement, nervousness, faint feeling, headache, insomnia, nightmares Gastrointestinal: Constipation, nausea, vomiting |
|
| Drug Interactions |
|
CYP2C, 2C8, and 2C19 enzyme substrate |
|
| Mechanism of Action |
|
Increases seizure threshold in the motor cortex; depresses monosynaptic and polysynaptic transmission in the CNS |
|
| Pharmacodynamics/Kinetics |
|
Onset of action: 20-60 minutes Duration: 6-8 hours Absorption: Oral: ~50% Serum half-life: 34 hours |
|
| Usual Dosage |
|
Oral: Children: 6-12 mg/kg/day in 2-4 divided doses Adults: 200-600 mg/day in 2-4 divided doses Sedation: Children: <5 years: 16-32 mg 3-4 times/day >5 years: 32-64 mg 3-4 times/day Adults: 32-100 mg 3-4 times/day Dosing adjustment in renal or hepatic impairment: Use with caution and reduce dosages |
|
| Dietary Considerations |
|
High doses of pyridoxine may decrease drug effect; barbiturates may increase the metabolism of vitamin D & K; dietary requirements of vitamin D, K, C, B12, folate and calcium may be increased with long-term use |
|
| Mental Health: Effects on Mental Status |
|
Dizziness and drowsiness are common; may cause confusion, nervousness, depression, nightmares, or insomnia; may rarely cause hallucinations |
|
| Mental Health: Effects on Psychiatric Treatment |
|
May rarely cause agranulocytosis; use caution with clozapine and carbamazepine; may induce hepatic enzymes resulting in an increase or decrease effect of concurrent psychotropic; monitor to altered response |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Patient Information |
|
May cause drowsiness, may impair coordination and judgment; do not discontinue abruptly; notify physician of dark urine, pale stools, jaundice, abdominal pain, persistent nausea, and vomiting; do not skip doses |
|
| Nursing Implications |
|
High doses of pyridoxine may decrease drug effect |
|
| Dosage Forms |
|
Tablet: 32 mg, 50 mg, 100 mg |
|
| References |
|
Pond SM, Olson KR, Osterloh JD, et al, "Randomized Study of the Treatment of Phenobarbital Overdose With Repeated Doses of Activated Charcoal," JAMA, 1984, 251(23):3104-8. Zawada ET, Nappi J, Done G, et al, "Advances in the Hemodialysis Management of Phenobarbital Overdose," South Med J, 1983, 76(1):6-8. |
|
|
Copyright © 2007 Drugs Area |
